RxDoctor Payments Data

Erika Bolton

Family · Montgomery, ALNPI 1528453198

Payments from drug & device makers

$8,954in general payments, 2019–2025

Across 530 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$804
  • Lilly USA, LLC$701
  • Pfizer$666
  • Novo Nordisk$565
  • Astellas Pharma US Inc$525
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$8,86999%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,954 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$70,643
Medicare patients
380
Services billed
1,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$49,858
EliquisApixaban71$47,954
JanuviaSitagliptin Phosphate41$44,124
JardianceEmpagliflozin37$31,868
MounjaroTirzepatide30$30,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,602
MyrbetriqMirabegron34$15,191
FarxigaDapagliflozin Propanediol18$14,572
Breo ElliptaFluticasone/Vilanterol24$11,602
LinzessLinaclotide13$8,756
GemtesaVibegron13$7,447
Repatha SyringeEvolocumab12$6,465
VascepaIcosapent Ethyl11$4,039
Levothyroxine Sodium102$2,105
Metoprolol Succinate78$1,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$565$49,85853 claims
PfizerEliquis$666$47,95471 claims
MerckJanuvia$267$44,12441 claims
Boehringer IngelheimJardiance$297$31,86837 claims
Lilly USA, LLCMounjaro$701$30,75230 claims
GSKTrelegy Ellipta, Breo Ellipta$393$28,20541 claims
Astellas Pharma US IncMyrbetriq$525$15,19134 claims
AstraZenecaFarxiga$417$14,57218 claims
AbbVieLinzess, Synthroid$1,029$9,91327 claims
Sumitomo Pharma America, Inc.Gemtesa$378$7,44713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →